Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9257121 | 0.80 | NFE2L2 (0.41) | MAOBMAOANFE2L2KMT2AATM | |
| SCHEMBL9051513 | 0.78 | MAOA (0.42) | MAOBMAOANFE2L2KMT2AMEN1 | |
| SCHEMBL27785246 | 0.78 | NFE2L2 (0.40) | MAOBMAOANFE2L2KMT2AATM | |
| SCHEMBL20072412 | 0.78 | CA1 (0.55) | NOS3ALDH1A1CYP1A2HPGDACHE | |
| SCHEMBL12835038 | 0.76 | MAOB (0.41) | MAOBMAOAKMT2AMEN1ATM | |
| SCHEMBL742569 | 0.76 | MAOA (0.41) | MAOBMAOANFE2L2KMT2AMEN1 | |
| SCHEMBL660921 | 0.76 | LMNA (0.64) | MAOBKMT2AMEN1POLBATM | |
| SCHEMBL16424483 | 0.76 | MAOB (0.46) | MAOBMAOAKMT2AMEN1NOS1 | |
| SCHEMBL12644763 | 0.76 | NFE2L2 (0.39) | MAOBMAOANFE2L2KMT2AATM | |
| SCHEMBL10451909 | 0.76 | MAOA (0.46) | MAOBMAOANFE2L2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109897022-B | Sphaelactone derivative, pharmaceutical composition thereof, preparation method and application thereof | 中国医学科学院药物研究所 | 2021-09-14 | — | — | CN | disclosed |
| CN-112876495-A | Parthenolide derivative, pharmaceutical composition thereof, preparation method and application thereof | 中国医学科学院药物研究所 | 2021-06-01 | — | — | CN | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8138344-B2 | Process for the preparation of rapamycin derivatives | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-8138344-B2 | Process for the preparation of rapamycin derivatives | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7601840-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090012298-A1 | Process for the Preparation of Rapamycin Derivatives | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012298-A1 | Process for the Preparation of Rapamycin Derivatives | NOVARTIS AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2007085400-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | NOVARTIS AG (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | RNMT, VEGFA, VHL | MAOB 1572/4885MAOA 1907/4885NFE2L2 68/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | MAOB 706/4885MAOA 1464/4885NFE2L2 158/4885 |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | MAOB 1594/4885MAOA 1749/4885NFE2L2 47/4885 |
| US-20090012298-A1 | Process for the Preparation of Rapamycin Derivatives | MLST8, RICTOR, MTOR | MAOB 2861/4885MAOA 3503/4885NFE2L2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.